Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: Insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease

Proteomics

Volumn 11, Issue 21, 2011, Pages 4243-4256

  Robinson, Renã A S ^a   Joshi, Gururaj ^a   Huang, Quanzhen ^a   Sultana, Rukhsana ^a   Baker, Austin S ^a   Cai, Jian ^b   Pierce, William ^b   St Clair, Daret K ^a   Markesbery, William R ^c   Allan Butterfield, D ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer disease; Animal proteomics; APP PS1; Mild cognitive impairment; N acetylcysteine; Oxidative stress; Protein oxidation

Indexed keywords

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATASE; ALPHA ENOLASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BRAIN PROTEIN; CALBINDIN; COFILIN 1; CYTOCHROME C OXIDASE; CYTOCHROME C OXIDASE SUBUNIT 5A; FRUCTOSE BISPHOSPHATE ALDOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE A; FRUCTOSE BISPHOSPHATE ALDOLASE C; GLUTAMATE AMMONIA LIGASE; GLUTAMATE DEHYDROGENASE; GLUTAMATE DEHYDROGENASE 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90ALPHA; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL PROTEIN; PRESENILIN 1; PROHIBITIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE SUBUNIT ALPHA; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE SUBUNIT DELTA; PYRUVATE KINASE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNAPTOSOMAL ASSOCIATED PROTEIN 25A; UNCLASSIFIED DRUG; V TYPE PROTON ADENOSINE TRIPHOSPHATASE SUBUNIT B; APP PROTEIN, HUMAN; PROTEOME; SCAVENGER;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; FUNCTIONAL PROTEOMICS; GENE MUTATION; IN VIVO STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; BRAIN; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE TARGETING; GENETICS; HUMAN; METABOLISM; MUTATION; PROTEOMICS;

ANIMALIA; MUS;

ACETYLCYSTEINE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; FREE RADICAL SCAVENGERS; GENE EXPRESSION REGULATION; GENE KNOCK-IN TECHNIQUES; HUMANS; MICE; MILD COGNITIVE IMPAIRMENT; MUTATION; PRESENILIN-1; PROTEOME; PROTEOMICS;

EID: 84856593034     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000523     Document Type: Article

References (73)

1. Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., Evans, D. A., Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60, 1119-1122.
2. Butterfield, D. A., Lauderback, C. M., Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 2002, 32, 1050-1060.
3. Lovell, M. A., Gabbita, S. P., Markesbery, W. R., Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J. Neurochem. 1999, 72, 771-776.
4. Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D. et al., Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 1993, 34, 609-616.
5. Nunomura, A., Perry, G., Pappolla, M. A., Wade, R. et al., RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 1999, 19, 1959-1964.
6. Wang, J., Xiong, S., Xie, C., Markesbery, W. R., Lovell, M. A., Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J. Neurochem. 2005, 93, 953-962.
7. Halliwell, B., Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001, 18, 685-716.
8. Lauderback, C. M., Hackett, J. M., Huang, F. F., Keller, J. N. et al., The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J. Neurochem. 2001, 78, 413-416.
9. Markesbery, W. R., Lovell, M. A., Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging 1998, 19, 33-36.
10. Beckman, K. B., Ames, B. N., The free radical theory of aging matures. Physiol. Rev. 1998, 78, 547-581.
11. Markesbery, W. R., Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 1997, 23, 134-147.
12. Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R. et al., A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 1997, 336, 1216-1222.
13. Butterfield, D. A., Drake, J., Pocernich, C., Castegna, A., Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 2001, 7, 548-554.
14. Casserly, I., Topol, E., Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 2004, 363, 1139-1146.
15. Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K. et al., Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19, 939-945.
16. Mohmmad Abdul, H., Sultana, R., Keller, J. N., St Clair, D. K. et al., Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. J. Neurochem. 2006, 96, 1322-1335.
17. Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K. et al., Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17, 1005-1013.
18. van Groen, T., Kiliaan, A. J., Kadish, I., Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. Neurobiol. Dis. 2006, 23, 653-662.
19. van Groen, T., Liu, L., Ikonen, S., Kadish, I., Diffuse amyloid deposition, but not plaque number, is reduced in amyloid precursor protein/presenilin 1 double-transgenic mice by pathway lesions. Neuroscience 2003, 119, 1185-1197.
20. Abdul, H. M., Sultana, R., St Clair, D. K., Markesbery, W. R., Butterfield, D. A., Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radic. Biol. Med. 2008, 45, 1420-1425.
21. Huang, Q., Aluise, C. D., Joshi, G., Sultana, R. et al., Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment. J. Neurosci. Res. 2010, 88, 2618-2629.
22. Prescott, L. F., Park, J., Ballantyne, A., Adriaenssens, P., Proudfoot, A. T., Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 1977, 2, 432-434.
23. Benzi, G., Moretti, A., Are reactive oxygen species involved in Alzheimer's disease? Neurobiol. Aging 1995, 16, 661-674.
24. Butterfield, D., Castegna, A., Pocernich, C., Drake, J. et al., Nutritional approaches to combat oxidative stress in Alzheimer's disease. J. Nutr. Biochem. 2002, 13, 444.
25. Anderson, M. E., Luo, J. L., Glutathione therapy: from prodrugs to genes. Semin. Liver Dis. 1998, 18, 415-424.
26. Pocernich, C. B., La Fontaine, M., Butterfield, D. A., In-vivo glutathione elevation protects against hydroxyl free radicalinduced protein oxidation in rat brain. Neurochem. Int. 2000, 36, 185-191.
27. Koppal, T., Drake, J., Butterfield, D. A., In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage. Biochim. Biophys. Acta 1999, 1453, 407-411.
28. Fontaine, M. A., Geddes, J. W., Banks, A., Butterfield, D. A., Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. J. Neurochem. 2000, 75, 1709-1715.
29. Pocernich, C. B., Cardin, A. L., Racine, C. L., Lauderback, C. M., Butterfield, D. A., Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem. Int. 2001, 39, 141-149.
30. Farr, S. A., Poon, H. F., Dogrukol-Ak, D., Drake, J. et al., The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J. Neurochem. 2003, 84, 1173-1183.
31. Chetelat, G., Desgranges, B., de la Sayette, V., Viader, F., Eustache, F., [At the boundary between normal aging and Alzheimer disease]. Rev. Neurol. (Paris) 2004, 160, S55-S63.
32. Petersen, R. C., Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 2000, 15, 93-101.
33. Reaume, A. G., Howland, D. S., Trusko, S. P., Savage, M. J. et al., Enhanced amyloidogenic processing of the betaamyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Abeta sequence. J. Biol. Chem. 1996, 271, 23380-23388.
34. Siman, R., Reaume, A. G., Savage, M. J., Trusko, S. et al., Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J. Neurosci. 2000, 20, 8717-8726.
35. Anantharaman, M., Tangpong, J., Keller, J. N., Murphy, M. P. et al., Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease. Am. J. Pathol. 2006, 168, 1608-1618.
36. Andreassen, O. A., Dedeoglu, A., Klivenyi, P., Beal, M. F., Bush, A. I., N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 2000, 11, 2491-2493.
37. Varadarajan, S., Yatin, S., Aksenova, M., Butterfield, D. A., Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 2000, 130, 184-208.
38. Murphy, M. P., Beckett, T. L., Ding, Q., Patel, E. et al., Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol. Dis. 2007, 27, 301-311.
39. Butterfield, D. A., Gnjec, A., Poon, H. F., Castegna, A. et al., Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J. Alzheimers Dis. 2006, 10, 391-397.
40. Butterfield, D. A., Sultana, R., Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J. Alzheimers Dis. 2007, 12, 61-72.
41. Sultana, R., Boyd-Kimball, D., Cai, J., Pierce, W. M. et al., Proteomics analysis of the Alzheimer's disease hippocampal proteome. J. Alzheimers Dis. 2007, 11, 153-164.
42. Reed, T. T., Pierce, W. M., Jr., Turner, D. M., Markesbery, W. R., Butterfield, D. A., Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J. Cell. Mol. Med. 2009, 8B, 2019-2029.
43. Sultana, R., Perluigi, M., Butterfield, D. A., Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol. 2009, 118, 131-150.
44. Pettegrew, J. W., Panchalingam, K., Klunk, W. E., McClure, R. J., Muenz, L. R., Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol. Aging 1994, 15, 117-132.
45. Leyva, J. A., Bianchet, M. A., Amzel, L. M., Understanding ATP synthesis: structure and mechanism of the F1-ATPase (Review). Mol. Membr. Biol. 2003, 20, 27-33.
46. Harris, L. K., Black, R. T., Golden, K. M., Reeves, T. M. et al., Traumatic brain injury-induced changes in gene expression and functional activity of mitochondrial cytochrome C oxidase. J. Neurotrauma 2001, 18, 993-1009.
47. Castegna, A., Aksenov, M., Aksenova, M., Thongboonkerd, V. et al., Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxyterminal hydrolase L-1. Free Radic. Biol. Med. 2002, 33, 562-571.
48. Lee, H. G., Zhu, X., Ghanbari, H. A., Ogawa, O. et al., Differential regulation of glutamate receptors in Alzheimer's disease. Neurosignals 2002, 11, 282-292.
49. Foster, T. C., Sharrow, K. M., Masse, J. R., Norris, C. M., Kumar, A., Calcineurin links Ca21 dysregulation with brain aging. J. Neurosci. 2001, 21, 4066-4073.
50. Sultana, R., Butterfield, D. A., Alterations of some membrane transport proteins in Alzheimer's disease: role of amyloid beta-peptide. Mol. Biosyst. 2008, 4, 36-41.
51. Haughey, N. J., Nath, A., Chan, S. L., Borchard, A. C. et al., Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J. Neurochem. 2002, 83, 1509-1524.
52. Mattson, M. P., Chan, S. L., Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 2003, 34, 385-397.
53. Sama, M. A., Mathis, D. M., Furman, J. L., Abdul, H. M. et al., Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity. J. Biol. Chem. 2008, 283, 21953-21964.
54. Butterfield, D. A., Poon, H. F., St Clair, D., Keller, J. N. et al., Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol. Dis. 2006, 22, 223-232.
55. Sultana, R., Boyd-Kimball, D., Poon, H. F., Cai, J. et al., Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiol. Aging 2006, 27, 918-925.
56. Lu, K. P., Finn, G., Lee, T. H., Nicholson, L. K., Prolyl cis-trans isomerization as a molecular timer. Nat. Chem. Biol. 2007, 3, 619-629.
57. Butterfield, D. A., Abdul, H. M., Opii, W., Newman, S. F. et al., Pin1 in Alzheimer's disease. J. Neurochem. 2006, 98, 1697-1706.
58. Lu, K. P., Phosphorylation-dependent prolyl isomerization: a novel cell cycle regulatory mechanism. Prog. Cell Cycle Res. 2000, 4, 83-96.
59. Pastorino, L., Sun, A., Lu, P. J., Zhou, X. Z. et al., The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 2006, 440, 528-534.
60. Butterfield, D. A., Reed, T., Newman, S. F., Sultana, R., Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 2007, 43, 658-677.
61. Scheff, S. W., Price, D. A., Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol. Aging 2003, 24, 1029-1046.
62. Poon, H. F., Vaishnav, R. A., Getchell, T. V., Getchell, M. L., Butterfield, D. A., Quantitative proteomics analysis of differential protein expression and oxidative modification of specific proteins in the brains of old mice. Neurobiol. Aging 2006, 27, 1010-1019.
63. Yao, P. J., Zhu, M., Pyun, E. I., Brooks, A. I. et al., Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol. Dis. 2003, 12, 97-109.
64. Poon, H. F., Vaishnav, R. A., Butterfield, D. A., Getchell, M. L., Getchell, T. V., Proteomic identification of differentially expressed proteins in the aging murine olfactory system and transcriptional analysis of the associated genes. J. Neurochem. 2005, 94, 380-392.
65. Curti, D., Benzi, G., Age-related modification of enzyme activities in synaptosomes isolated from rat cerebral cortex. J. Neurosci. Res. 1989, 22, 346-350.
66. Curti, D., Benzi, G., Role of synaptosomal enzymatic alterations and drug treatment in brain aging. Clin. Neuropharmacol. 1990, 13, S59-S72.
67. Poon, H. F., Shepherd, H. M., Reed, T. T., Calabrese, V. et al., Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with age-related impaired cellular processes: mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis. Neurobiol. Aging 2006, 27, 1020-1034.
68. Perluigi, M., Sultana, R., Cenini, G., Di Domenico, F. et al., Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin. Appl. 2009, 3, 682-693.
69. Coates, P. J., Nenutil, R., McGregor, A., Picksley, S. M. et al., Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp. Cell Res. 2001, 265, 262-273.
70. Theiss, A. L., Idell, R. D., Srinivasan, S., Klapproth, J. M. et al., Prohibitin protects against oxidative stress in intestinal epithelial cells. FASEB J. 2007, 21, 197-206.
71. Theiss, A. L., Vijay-Kumar, M., Obertone, T. S., Jones, D. P. et al., Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice. Gastroenterology 2009, 137, 199-208, 208 e191-e196.
72. Nijtmans, L. G., Artal, S. M., Grivell, L. A., Coates, P. J., The mitochondrial PHB complex: roles in mitochondrial respiratory complex assembly, ageing and degenerative disease. Cell Mol. Life Sci. 2002, 59, 143-155.
73. Nijtmans, L. G., de Jong, L., Artal Sanz, M., Coates, P. J. et al., Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J. 2000, 19, 2444-2451.